Holen Sie sich die Stockscreener-App
109.40
0.60%
0.6478
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Can Axsome Therapeutics Inc. continue delivering strong returnsWeekly Profit Analysis & Fast Exit Strategy with Risk Control - thegnnews.com
Connor Clark & Lunn Investment Management Ltd. Has $20.52 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
XTX Topco Ltd Sells 9,794 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Virtu Financial LLC Takes $931,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Informed Momentum Co LLC Acquires New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Cantor Fitzgerald Has Positive View of AXSM FY2026 Earnings - MarketBeat
HC Wainwright Issues Negative Estimate for AXSM Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat
Cantor Fitzgerald Issues Negative Forecast for AXSM Earnings - MarketBeat
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Equities Analysts Issue Forecasts for AXSM Q3 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript - MSN
Bank of America Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
TD Asset Management Inc Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Royal Bank Of Canada Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $189.00 - MarketBeat
Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth - MSN
Axsome Therapeutics (NASDAQ:AXSM) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Federated Hermes Inc. Acquires Shares of 25,990 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Jumps 5% as Q2 Revenue Surpasses Projections - MSN
J. Safra Sarasin Holding AG Makes New $1.13 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Earnings Call Highlights Robust Growth - The Globe and Mail
Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation - TipRanks
Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating - TipRanks
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
Shareholders Have Faith in Loss-making Axsome Therapeutics (NASDAQ:AXSM) as Stock Climbs 6.1% in Past Week, Taking Three-year Gain to 146% - 富途牛牛
Axsome Therapeutics: BofA Securities Reiterates Buy Rating, Raises PT to $176. - AInvest
RBC Capital Reiterates Outperform on Axsome Therapeutics, Raises PT to $189 - AInvest
Axsome Therapeutics Reports Strong Q2 2025 Performance - The Globe and Mail
RBC Raises Price Target on Axsome Therapeutics to $189 From $184, Keeps Outperform Rating - MarketScreener
Axsome: Q2 Earnings Snapshot - New Haven Register
Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
0.07%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):